Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630390 · ClinicalTrials.gov registry record · Phase 2
Daridorexant to Prevent Delirium After Heart Surgery
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT06630390 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 11 participants.
The verdict
NCT06630390, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The goal of this phase 2 clinical trial is to demonstrate the feasibility of the current study methods and obtain preliminary data for an adequately powered trial of daridorexant with the aim of preventing delirium after heart surgery. The main aims this feasibility trial aims to answer are to demonstrate: (1) the feasibility of study recruitment; (2) the ability deliver study compounds to subjects according to the proposed methods; and (3) completeness of data capture; and (4) recording of potential adverse events. Participants will: (1) complete a baseline visit; (2) take the study drug--either daridorexant or placebo--each of the first 3 nights after heart surgery; and (3) be evaluated for sleep and delirium each of the first three days after heart surgery.
Interventions
- OTHER Placebo
- DRUG Daridorexant 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2025-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06630390
The ClinicalTrials.gov registry entry for NCT06630390 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06630390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06630390 about?
NCT06630390 is a clinical study titled "Daridorexant to Prevent Delirium After Heart Surgery". The goal of this phase 2 clinical trial is to demonstrate the feasibility of the current study methods and obtain preliminary data for an adequately powered trial of daridorexant with the aim of preventing delirium after heart surgery. The main aims this feasibility trial aims to answer are to demon...
What is the current status of trial NCT06630390?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-11-11. Estimated completion is 2025-02-16.
What interventions are being tested in trial NCT06630390?
The interventions under investigation include: Placebo (OTHER), Daridorexant 50 mg (DRUG).
Who is sponsoring clinical trial NCT06630390?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.